Mereo BioPharma Group plc (MAH0) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group plc (MAH0) has a Cash Flow-to-Debt Ratio of -1.54x as of December 2025, meaning its operating cash flow of €-7.68 Million could theoretically repay -2% of its total liabilities (€5.00 Million) in one year. Check Mereo BioPharma Group plc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group plc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Mereo BioPharma Group plc across 10 annual periods. Also explore total assets of Mereo BioPharma Group plc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group plc (2016–2025)
Year-by-year debt coverage analysis for Mereo BioPharma Group plc. For market capitalisation and broader financial context, see how much is Mereo BioPharma Group plc worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | €-30.97 Million | €5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | €-32.83 Million | €15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | €-21.13 Million | €15.96 Million | ▲ +10.6% |
| 2022 | -1.48x | €-38.82 Million | €26.21 Million | ▼ -986.0% |
| 2021 | -0.14x | €-5.24 Million | €38.41 Million | ▲ +62.5% |
| 2020 | -0.36x | €-28.34 Million | €77.92 Million | ▲ +63.4% |
| 2019 | -0.99x | €-45.93 Million | €46.19 Million | ▼ -48.3% |
| 2018 | -0.67x | €-23.14 Million | €34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | €-32.15 Million | €33.85 Million | ▲ +76.0% |
| 2016 | -3.95x | €-29.66 Million | €7.51 Million | — |